CA2342622A1 — New substituted indolinones,their preparation and their use as medicaments
Assigned to Boehringer Ingelheim Pharma GmbH and Co KG · Expires 2000-04-06 · 26y expired
What this patent protects
The invention relates to novel substituted indolinones of general formula (I), wherein X and R1 to R5 have the meanings given in claim no.1, and to isomers and salts thereof with useful properties. The above compounds of general formula (I), wherein R1 represents a hydrogen atom,…
USPTO Abstract
The invention relates to novel substituted indolinones of general formula (I), wherein X and R1 to R5 have the meanings given in claim no.1, and to isomers and salts thereof with useful properties. The above compounds of general formula (I), wherein R1 represents a hydrogen atom, a C1-3-alkyl group or a pro-drug radical, have useful pharmacological properties, especially an inhibitory effect on various kinases, on viral cyclin and on receptor tyrosine kinases. The other compounds of general formula (I), wherein R1 does not represent a hydrogen atom, a C1-3-alkyl group or pro-drug radical, represent useful intermediate products for producing the above-mentioned compounds.
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.